Acutaas Chemicals Ltd (ACUTAAS)
₹3,259.50
Mkt cap
₹26,686 Cr
P/E ratio
69.10
P/B
16.14
Div yield
0.05%
ROE
24.00%
ROCE
31.60%
EPS (TTM)
₹47.17
Book value
₹202
52W range
1,148–3,695
Sector
Healthcare
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals. [1]
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−11.78% from high₹3,260
₹1,148+183.90% from low₹3,695
Current
₹3,259.50
Prev close
₹3,251.90
Day
+0.23%
Price performance
1D
+0.23%
1W
−10.85%
1M
−1.23%
3M
+36.10%
6M
+100.40%
1Y
+169.69%
YTD
+86.33%
Financials
FRevenue, profit & margin
P/E ratio
69.1×
ACUTAAS is 103% above the sector median of 34.0×
ACUTAAS69.1×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 154 | 172 | 166 | 225 | 177 | 247 | 275 | 308 | 207 | 306 | 393 | 433 | 330 | |
| Expenses | 120 | 148 | 140 | 182 | 147 | 198 | 206 | 224 | 156 | 211 | 243 | 249 | 217 | |
| Operating Profit | 34 | 25 | 27 | 43 | 30 | 49 | 69 | 85 | 51 | 95 | 151 | 184 | 113 | |
| OPM % | 22% | 14% | 16% | 19% | 17% | 20% | 25% | 28% | 25% | 31% | 38% | 42% | 34% | |
| Other Income | 1 | -30 | 3 | 1 | 1 | 8 | 2 | 6 | 16 | 10 | 5 | 11 | 2 | |
| Interest | 1 | 1 | 3 | 2 | 4 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Depreciation | 4 | 4 | 4 | 5 | 6 | 7 | 6 | 7 | 8 | 8 | 10 | 10 | 10 | |
| Profit before tax | 31 | -10 | 24 | 37 | 20 | 50 | 63 | 83 | 58 | 96 | 145 | 184 | 104 | |
| Tax % | 28% | 71% | 25% | 31% | 26% | 25% | 28% | 24% | 24% | 25% | 27% | 27% | 28% | |
| Net Profit | 22 | -17 | 18 | 26 | 15 | 38 | 45 | 63 | 44 | 72 | 106 | 134 | 75 | |
| EPS in Rs | 2.71 | -2.55 | 2.27 | 3.41 | 1.71 | 4.56 | 5.49 | 7.63 | 5.41 | 8.82 | 13.19 | 16.09 | 9.07 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +1.20% · closed higher next day 12 of last 18
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 9 Nov '23◦ | 13 Feb '24 | 12 May '24◦ | 13 Aug '24 | 29 Oct '24◦ | 29 Jan '25◦ | 2 May '25◦ | 30 Jul '25 | 17 Oct '25 | 28 Jan '26 | 30 Apr '26 | 24 Jul '26 |
| Earnings day | −2.90% | +4.80% | +2.00% | −3.79% | +5.43% | +4.45% | +3.47% | +4.56% | +6.02% | +7.78% | +3.66% | −5.99% |
| +1 day | −2.23% | +4.78% | +0.64% | −4.79% | +8.63% | +5.63% | −2.67% | +13.73% | +13.53% | +11.93% | +6.95% | — |
| +5 days | −2.60% | +4.91% | +3.10% | +2.79% | +13.41% | +16.32% | +1.91% | +12.72% | +10.38% | +15.09% | +9.27% | — |
| +15 days | −1.77% | +10.95% | +0.31% | +9.01% | +17.85% | −2.23% | +2.53% | +20.01% | +9.86% | +24.03% | +17.93% | — |
| +30 days | +7.77% | +4.30% | +8.65% | +29.47% | +15.95% | −3.35% | −5.87% | +23.56% | +11.72% | +26.60% | +23.75% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202632.66%Promoter
Promoters32.66%
FIIs21.61%2.13
DIIs19.55%0.05
Public26.16%2.08
Government0.01%
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Acutaas Chemical | ₹3,259.50 | 69.10 | 26,686 | 0.05% | 75 | +67.67% | 330 | +59.08% | 31.56% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports5
Concall transcripts52
PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026PPTApr 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptOct 2025PPTOct 2025RECOct 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024
Credit ratings3
Announcements5
Earnings Call Recording Pursuant To SEBI (LODR) Regulations, 2015 9h - Earnings call recording dated July 24, 2026 is available on Acutaas Chemicals’ website.Announcement under Regulation 30 (LODR)-Investor Presentation 14h - Investor Presentation on financial results for the first quarter ended June 30, 2026 is attached.Announcement under Regulation 30 (LODR)-Press Release / Media Release 14h - Acutaas Chemicals Q1 FY27 revenue rose 59.1% to ₹3,297mn; PAT rose 70.4% to ₹750mn.Unaudited Standalone And Consolidated Financial Results For First Quarter Ended June 30, 2026 15hBoard Meeting Outcome for Outcome Of Board Meeting Held On July 24, 2026 15h - Board approved Q1 FY27 unaudited standalone and consolidated results on July 24, 2026.